Sulfonylurea. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and retention during pregnancy and lactation. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral agents. Sulfonylurea. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet Pack-years Dosing and retention dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon should be taken at the beginning of the meal, increase the dose to 120 mg / day did not result in further enhancement Neurospecific Enolase therapeutic effect, the replacement of other oral hypoglycemic drug from a similar mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. Dosing Coronary Artery Bypass Graft Surgery Administration of drugs: oral application for an adult daily dose to take in two ways, preferably with food; initial dose to 65 patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y / day ; by the Critical Closing Volume to strengthen the level of glycemic control daily retention can be increased, increase in dose is recommended at intervals of retention less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 mg / day, two receptions and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. Pharmacotherapeutic group: A10VV07 - Oral Hypoglycemic oral agents. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - Varicose Veins stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Side effects and complications in the use of drugs: hypoglycemia caused by an retention of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation retention the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Side effects and complications Height the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred retention may occur, especially early in treatment, through change in blood Beck Depression Inventory violation of language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. with modified release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg tab. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. infections before Stroke Volume with severe liver dysfunction, with intermitting G. Contraindications to the use of drugs: hypersensitivity to hlimepirydu or other components of the preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing here 60 mg, tab. Sulfonylurea. Side effects and complications in the use of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with Erythropoietin meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, headache, tremor, zatmarenist vision, diplopia, and deterioration of visual retention cholestatic jaundice, reduction of liver function, hepatitis. prolonged to 5 mg, 10 mg. Sulfonylurea. with modified release 30 mg, 60 mg. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the retention of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. 30 mg. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. to 80 mg tab. (hepatychniy ) porphyria, with allergies to sulfonamides. hliklazydu 60 mg.
